nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—ADRA2A—type 2 diabetes mellitus	0.134	0.42	CbGaD
Paliperidone—HTR2C—type 2 diabetes mellitus	0.123	0.387	CbGaD
Paliperidone—CYP3A4—type 2 diabetes mellitus	0.0616	0.193	CbGaD
Paliperidone—DRD4—Bromocriptine—type 2 diabetes mellitus	0.0363	0.0861	CbGbCtD
Paliperidone—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0299	0.0708	CbGbCtD
Paliperidone—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0286	0.0679	CbGbCtD
Paliperidone—DRD3—Bromocriptine—type 2 diabetes mellitus	0.027	0.064	CbGbCtD
Paliperidone—DRD1—Bromocriptine—type 2 diabetes mellitus	0.026	0.0617	CbGbCtD
Paliperidone—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.026	0.0617	CbGbCtD
Paliperidone—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0247	0.0585	CbGbCtD
Paliperidone—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0208	0.0494	CbGbCtD
Paliperidone—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.019	0.0451	CbGbCtD
Paliperidone—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0179	0.0425	CbGbCtD
Paliperidone—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0172	0.0407	CbGbCtD
Paliperidone—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0172	0.0407	CbGbCtD
Paliperidone—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0164	0.039	CbGbCtD
Paliperidone—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0158	0.0375	CbGbCtD
Paliperidone—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0103	0.0243	CbGbCtD
Paliperidone—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0083	0.0197	CbGbCtD
Paliperidone—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0082	0.0194	CbGbCtD
Paliperidone—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00766	0.0182	CbGbCtD
Paliperidone—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0073	0.0173	CbGbCtD
Paliperidone—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00668	0.0158	CbGbCtD
Paliperidone—CYP3A5—Losartan—type 2 diabetes mellitus	0.00634	0.015	CbGbCtD
Paliperidone—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00629	0.0149	CbGbCtD
Paliperidone—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00603	0.0143	CbGbCtD
Paliperidone—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00584	0.0138	CbGbCtD
Paliperidone—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00528	0.0125	CbGbCtD
Paliperidone—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.004	0.00949	CbGbCtD
Paliperidone—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00384	0.0091	CbGbCtD
Paliperidone—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00384	0.0091	CbGbCtD
Paliperidone—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00363	0.00861	CbGbCtD
Paliperidone—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0027	0.00641	CbGbCtD
Paliperidone—CYP3A4—Losartan—type 2 diabetes mellitus	0.00247	0.00586	CbGbCtD
Paliperidone—HTR2A—arteriole—type 2 diabetes mellitus	0.00209	0.104	CbGeAlD
Paliperidone—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00133	0.0661	CbGeAlD
Paliperidone—DRD1—nerve—type 2 diabetes mellitus	0.00129	0.0642	CbGeAlD
Paliperidone—HTR1B—artery—type 2 diabetes mellitus	0.00106	0.0524	CbGeAlD
Paliperidone—HTR1D—artery—type 2 diabetes mellitus	0.00102	0.0507	CbGeAlD
Paliperidone—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000896	0.0445	CbGeAlD
Paliperidone—HTR2A—hindlimb—type 2 diabetes mellitus	0.000829	0.0411	CbGeAlD
Paliperidone—DRD2—nerve—type 2 diabetes mellitus	0.000764	0.0379	CbGeAlD
Paliperidone—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.00076	0.0377	CbGeAlD
Paliperidone—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000646	0.0321	CbGeAlD
Paliperidone—HTR2A—artery—type 2 diabetes mellitus	0.000508	0.0252	CbGeAlD
Paliperidone—HTR2A—nerve—type 2 diabetes mellitus	0.000504	0.025	CbGeAlD
Paliperidone—Risperidone—ADRA2A—type 2 diabetes mellitus	0.000486	0.168	CrCbGaD
Paliperidone—ADRA1B—kidney—type 2 diabetes mellitus	0.000475	0.0236	CbGeAlD
Paliperidone—Iloperidone—ADRA2A—type 2 diabetes mellitus	0.000456	0.158	CrCbGaD
Paliperidone—Risperidone—HTR2C—type 2 diabetes mellitus	0.000448	0.155	CrCbGaD
Paliperidone—HTR2A—endothelium—type 2 diabetes mellitus	0.000429	0.0213	CbGeAlD
Paliperidone—Iloperidone—HTR2C—type 2 diabetes mellitus	0.00042	0.145	CrCbGaD
Paliperidone—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000367	0.0182	CbGeAlD
Paliperidone—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000355	0.0176	CbGeAlD
Paliperidone—HTR1D—kidney—type 2 diabetes mellitus	0.000348	0.0173	CbGeAlD
Paliperidone—Iloperidone—CYP2E1—type 2 diabetes mellitus	0.000333	0.115	CrCbGaD
Paliperidone—Iloperidone—CYP1A2—type 2 diabetes mellitus	0.000317	0.11	CrCbGaD
Paliperidone—DRD2—retina—type 2 diabetes mellitus	0.000316	0.0157	CbGeAlD
Paliperidone—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000301	0.0149	CbGeAlD
Paliperidone—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000296	0.0147	CbGeAlD
Paliperidone—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.00029	0.0144	CbGeAlD
Paliperidone—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000287	0.0142	CbGeAlD
Paliperidone—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000273	0.0136	CbGeAlD
Paliperidone—ADRA2C—kidney—type 2 diabetes mellitus	0.000255	0.0126	CbGeAlD
Paliperidone—ADRA2C—pancreas—type 2 diabetes mellitus	0.000253	0.0125	CbGeAlD
Paliperidone—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000248	0.0123	CbGeAlD
Paliperidone—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000242	0.012	CbGeAlD
Paliperidone—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000241	0.0119	CbGeAlD
Paliperidone—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000229	0.0114	CbGeAlD
Paliperidone—Risperidone—CYP3A4—type 2 diabetes mellitus	0.000224	0.0773	CrCbGaD
Paliperidone—CYP3A5—kidney—type 2 diabetes mellitus	0.000213	0.0106	CbGeAlD
Paliperidone—CYP3A5—pancreas—type 2 diabetes mellitus	0.000212	0.0105	CbGeAlD
Paliperidone—Iloperidone—CYP3A4—type 2 diabetes mellitus	0.00021	0.0725	CrCbGaD
Paliperidone—HTR2A—retina—type 2 diabetes mellitus	0.000209	0.0104	CbGeAlD
Paliperidone—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000207	0.0103	CbGeAlD
Paliperidone—ADRA2A—pancreas—type 2 diabetes mellitus	0.000202	0.01	CbGeAlD
Paliperidone—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000198	0.00982	CbGeAlD
Paliperidone—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000192	0.00953	CbGeAlD
Paliperidone—HRH1—adipose tissue—type 2 diabetes mellitus	0.000186	0.00925	CbGeAlD
Paliperidone—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000183	0.00909	CbGeAlD
Paliperidone—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000177	0.00876	CbGeAlD
Paliperidone—HTR2A—kidney—type 2 diabetes mellitus	0.000173	0.00857	CbGeAlD
Paliperidone—ADRA1A—liver—type 2 diabetes mellitus	0.000169	0.00838	CbGeAlD
Paliperidone—ADRA2C—liver—type 2 diabetes mellitus	0.000161	0.00799	CbGeAlD
Paliperidone—CYP3A4—kidney—type 2 diabetes mellitus	0.00016	0.00793	CbGeAlD
Paliperidone—CYP2D6—kidney—type 2 diabetes mellitus	0.000157	0.00781	CbGeAlD
Paliperidone—CYP3A5—liver—type 2 diabetes mellitus	0.000135	0.00668	CbGeAlD
Paliperidone—HTR2A—liver—type 2 diabetes mellitus	0.000109	0.00542	CbGeAlD
Paliperidone—CYP3A4—liver—type 2 diabetes mellitus	0.000101	0.00502	CbGeAlD
Paliperidone—CYP2D6—liver—type 2 diabetes mellitus	9.94e-05	0.00494	CbGeAlD
Paliperidone—Malaise—Losartan—type 2 diabetes mellitus	5.01e-05	0.00033	CcSEcCtD
Paliperidone—Anxiety—Irbesartan—type 2 diabetes mellitus	5e-05	0.00033	CcSEcCtD
Paliperidone—Hypersensitivity—Glyburide—type 2 diabetes mellitus	5e-05	0.00033	CcSEcCtD
Paliperidone—Nervous system disorder—Metformin—type 2 diabetes mellitus	5e-05	0.00033	CcSEcCtD
Paliperidone—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.99e-05	0.00033	CcSEcCtD
Paliperidone—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.99e-05	0.000329	CcSEcCtD
Paliperidone—Vertigo—Losartan—type 2 diabetes mellitus	4.99e-05	0.000329	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	4.99e-05	0.000329	CcSEcCtD
Paliperidone—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.99e-05	0.000329	CcSEcCtD
Paliperidone—Somnolence—Valsartan—type 2 diabetes mellitus	4.98e-05	0.000329	CcSEcCtD
Paliperidone—Syncope—Losartan—type 2 diabetes mellitus	4.98e-05	0.000328	CcSEcCtD
Paliperidone—Paraesthesia—Orlistat—type 2 diabetes mellitus	4.97e-05	0.000328	CcSEcCtD
Paliperidone—Leukopenia—Losartan—type 2 diabetes mellitus	4.97e-05	0.000328	CcSEcCtD
Paliperidone—Discomfort—Irbesartan—type 2 diabetes mellitus	4.96e-05	0.000327	CcSEcCtD
Paliperidone—Skin disorder—Metformin—type 2 diabetes mellitus	4.95e-05	0.000327	CcSEcCtD
Paliperidone—Immune system disorder—Ramipril—type 2 diabetes mellitus	4.94e-05	0.000326	CcSEcCtD
Paliperidone—Dyspepsia—Valsartan—type 2 diabetes mellitus	4.93e-05	0.000325	CcSEcCtD
Paliperidone—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	4.93e-05	0.000325	CcSEcCtD
Paliperidone—Dizziness—Bromocriptine—type 2 diabetes mellitus	4.91e-05	0.000324	CcSEcCtD
Paliperidone—Dry mouth—Irbesartan—type 2 diabetes mellitus	4.91e-05	0.000324	CcSEcCtD
Paliperidone—Palpitations—Losartan—type 2 diabetes mellitus	4.91e-05	0.000324	CcSEcCtD
Paliperidone—Nausea—Glimepiride—type 2 diabetes mellitus	4.89e-05	0.000323	CcSEcCtD
Paliperidone—Loss of consciousness—Losartan—type 2 diabetes mellitus	4.88e-05	0.000322	CcSEcCtD
Paliperidone—Nausea—Sitagliptin—type 2 diabetes mellitus	4.88e-05	0.000322	CcSEcCtD
Paliperidone—Dyspepsia—Orlistat—type 2 diabetes mellitus	4.87e-05	0.000321	CcSEcCtD
Paliperidone—Asthenia—Glyburide—type 2 diabetes mellitus	4.87e-05	0.000321	CcSEcCtD
Paliperidone—Decreased appetite—Valsartan—type 2 diabetes mellitus	4.87e-05	0.000321	CcSEcCtD
Paliperidone—Anorexia—Metformin—type 2 diabetes mellitus	4.86e-05	0.000321	CcSEcCtD
Paliperidone—Cough—Losartan—type 2 diabetes mellitus	4.84e-05	0.00032	CcSEcCtD
Paliperidone—Urticaria—Gliclazide—type 2 diabetes mellitus	4.84e-05	0.00032	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	4.84e-05	0.000319	CcSEcCtD
Paliperidone—Alopecia—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000319	CcSEcCtD
Paliperidone—Fatigue—Valsartan—type 2 diabetes mellitus	4.83e-05	0.000319	CcSEcCtD
Paliperidone—Body temperature increased—Gliclazide—type 2 diabetes mellitus	4.82e-05	0.000318	CcSEcCtD
Paliperidone—Abdominal pain—Gliclazide—type 2 diabetes mellitus	4.82e-05	0.000318	CcSEcCtD
Paliperidone—Oedema—Irbesartan—type 2 diabetes mellitus	4.81e-05	0.000318	CcSEcCtD
Paliperidone—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	4.81e-05	0.000318	CcSEcCtD
Paliperidone—Decreased appetite—Orlistat—type 2 diabetes mellitus	4.81e-05	0.000317	CcSEcCtD
Paliperidone—Pruritus—Glyburide—type 2 diabetes mellitus	4.8e-05	0.000317	CcSEcCtD
Paliperidone—Mental disorder—Ramipril—type 2 diabetes mellitus	4.79e-05	0.000316	CcSEcCtD
Paliperidone—Constipation—Valsartan—type 2 diabetes mellitus	4.79e-05	0.000316	CcSEcCtD
Paliperidone—Infection—Irbesartan—type 2 diabetes mellitus	4.78e-05	0.000316	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	4.78e-05	0.000315	CcSEcCtD
Paliperidone—Fatigue—Orlistat—type 2 diabetes mellitus	4.77e-05	0.000315	CcSEcCtD
Paliperidone—Hypotension—Metformin—type 2 diabetes mellitus	4.77e-05	0.000314	CcSEcCtD
Paliperidone—Malnutrition—Ramipril—type 2 diabetes mellitus	4.76e-05	0.000314	CcSEcCtD
Paliperidone—Erythema—Ramipril—type 2 diabetes mellitus	4.76e-05	0.000314	CcSEcCtD
Paliperidone—Shock—Irbesartan—type 2 diabetes mellitus	4.74e-05	0.000312	CcSEcCtD
Paliperidone—Pain—Orlistat—type 2 diabetes mellitus	4.73e-05	0.000312	CcSEcCtD
Paliperidone—Arthralgia—Losartan—type 2 diabetes mellitus	4.73e-05	0.000312	CcSEcCtD
Paliperidone—Myalgia—Losartan—type 2 diabetes mellitus	4.73e-05	0.000312	CcSEcCtD
Paliperidone—Chest pain—Losartan—type 2 diabetes mellitus	4.73e-05	0.000312	CcSEcCtD
Paliperidone—Vomiting—Bromocriptine—type 2 diabetes mellitus	4.72e-05	0.000312	CcSEcCtD
Paliperidone—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.000311	CcSEcCtD
Paliperidone—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	4.71e-05	0.000311	CcSEcCtD
Paliperidone—Anxiety—Losartan—type 2 diabetes mellitus	4.71e-05	0.000311	CcSEcCtD
Paliperidone—Tachycardia—Irbesartan—type 2 diabetes mellitus	4.7e-05	0.00031	CcSEcCtD
Paliperidone—Rash—Bromocriptine—type 2 diabetes mellitus	4.68e-05	0.000309	CcSEcCtD
Paliperidone—Dermatitis—Bromocriptine—type 2 diabetes mellitus	4.68e-05	0.000309	CcSEcCtD
Paliperidone—Skin disorder—Irbesartan—type 2 diabetes mellitus	4.68e-05	0.000308	CcSEcCtD
Paliperidone—Tension—Ramipril—type 2 diabetes mellitus	4.67e-05	0.000308	CcSEcCtD
Paliperidone—Discomfort—Losartan—type 2 diabetes mellitus	4.67e-05	0.000308	CcSEcCtD
Paliperidone—Dysgeusia—Ramipril—type 2 diabetes mellitus	4.66e-05	0.000308	CcSEcCtD
Paliperidone—Headache—Bromocriptine—type 2 diabetes mellitus	4.65e-05	0.000307	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	4.65e-05	0.000307	CcSEcCtD
Paliperidone—Diarrhoea—Glyburide—type 2 diabetes mellitus	4.65e-05	0.000307	CcSEcCtD
Paliperidone—Nervousness—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000305	CcSEcCtD
Paliperidone—Dry mouth—Losartan—type 2 diabetes mellitus	4.62e-05	0.000305	CcSEcCtD
Paliperidone—Anorexia—Irbesartan—type 2 diabetes mellitus	4.59e-05	0.000303	CcSEcCtD
Paliperidone—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	4.58e-05	0.000302	CcSEcCtD
Paliperidone—Paraesthesia—Metformin—type 2 diabetes mellitus	4.58e-05	0.000302	CcSEcCtD
Paliperidone—Muscle spasms—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000302	CcSEcCtD
Paliperidone—Confusional state—Losartan—type 2 diabetes mellitus	4.57e-05	0.000301	CcSEcCtD
Paliperidone—Feeling abnormal—Orlistat—type 2 diabetes mellitus	4.56e-05	0.000301	CcSEcCtD
Paliperidone—Dyspnoea—Metformin—type 2 diabetes mellitus	4.55e-05	0.0003	CcSEcCtD
Paliperidone—Somnolence—Metformin—type 2 diabetes mellitus	4.53e-05	0.000299	CcSEcCtD
Paliperidone—Anaphylactic shock—Losartan—type 2 diabetes mellitus	4.53e-05	0.000299	CcSEcCtD
Paliperidone—Oedema—Losartan—type 2 diabetes mellitus	4.53e-05	0.000299	CcSEcCtD
Paliperidone—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	4.53e-05	0.000299	CcSEcCtD
Paliperidone—Infection—Losartan—type 2 diabetes mellitus	4.5e-05	0.000297	CcSEcCtD
Paliperidone—Hypotension—Irbesartan—type 2 diabetes mellitus	4.5e-05	0.000297	CcSEcCtD
Paliperidone—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	4.49e-05	0.000296	CcSEcCtD
Paliperidone—Dyspepsia—Metformin—type 2 diabetes mellitus	4.49e-05	0.000296	CcSEcCtD
Paliperidone—Tremor—Ramipril—type 2 diabetes mellitus	4.46e-05	0.000294	CcSEcCtD
Paliperidone—Shock—Losartan—type 2 diabetes mellitus	4.46e-05	0.000294	CcSEcCtD
Paliperidone—Urticaria—Valsartan—type 2 diabetes mellitus	4.45e-05	0.000294	CcSEcCtD
Paliperidone—Nervous system disorder—Losartan—type 2 diabetes mellitus	4.44e-05	0.000293	CcSEcCtD
Paliperidone—Thrombocytopenia—Losartan—type 2 diabetes mellitus	4.44e-05	0.000293	CcSEcCtD
Paliperidone—Decreased appetite—Metformin—type 2 diabetes mellitus	4.43e-05	0.000293	CcSEcCtD
Paliperidone—Abdominal pain—Valsartan—type 2 diabetes mellitus	4.43e-05	0.000292	CcSEcCtD
Paliperidone—Tachycardia—Losartan—type 2 diabetes mellitus	4.42e-05	0.000292	CcSEcCtD
Paliperidone—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	4.42e-05	0.000291	CcSEcCtD
Paliperidone—Nausea—Bromocriptine—type 2 diabetes mellitus	4.41e-05	0.000291	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	4.4e-05	0.000291	CcSEcCtD
Paliperidone—Fatigue—Metformin—type 2 diabetes mellitus	4.4e-05	0.00029	CcSEcCtD
Paliperidone—Urticaria—Orlistat—type 2 diabetes mellitus	4.4e-05	0.00029	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	4.39e-05	0.000289	CcSEcCtD
Paliperidone—Abdominal pain—Orlistat—type 2 diabetes mellitus	4.38e-05	0.000289	CcSEcCtD
Paliperidone—Body temperature increased—Orlistat—type 2 diabetes mellitus	4.38e-05	0.000289	CcSEcCtD
Paliperidone—Asthenia—Gliclazide—type 2 diabetes mellitus	4.37e-05	0.000289	CcSEcCtD
Paliperidone—Agitation—Ramipril—type 2 diabetes mellitus	4.37e-05	0.000289	CcSEcCtD
Paliperidone—Constipation—Metformin—type 2 diabetes mellitus	4.36e-05	0.000288	CcSEcCtD
Paliperidone—Angioedema—Ramipril—type 2 diabetes mellitus	4.35e-05	0.000287	CcSEcCtD
Paliperidone—Paraesthesia—Irbesartan—type 2 diabetes mellitus	4.32e-05	0.000285	CcSEcCtD
Paliperidone—Anorexia—Losartan—type 2 diabetes mellitus	4.32e-05	0.000285	CcSEcCtD
Paliperidone—Vomiting—Glyburide—type 2 diabetes mellitus	4.32e-05	0.000285	CcSEcCtD
Paliperidone—Pruritus—Gliclazide—type 2 diabetes mellitus	4.31e-05	0.000285	CcSEcCtD
Paliperidone—Malaise—Ramipril—type 2 diabetes mellitus	4.29e-05	0.000283	CcSEcCtD
Paliperidone—Dyspnoea—Irbesartan—type 2 diabetes mellitus	4.29e-05	0.000283	CcSEcCtD
Paliperidone—Rash—Glyburide—type 2 diabetes mellitus	4.28e-05	0.000282	CcSEcCtD
Paliperidone—Somnolence—Irbesartan—type 2 diabetes mellitus	4.28e-05	0.000282	CcSEcCtD
Paliperidone—Dermatitis—Glyburide—type 2 diabetes mellitus	4.28e-05	0.000282	CcSEcCtD
Paliperidone—Vertigo—Ramipril—type 2 diabetes mellitus	4.28e-05	0.000282	CcSEcCtD
Paliperidone—Syncope—Ramipril—type 2 diabetes mellitus	4.27e-05	0.000282	CcSEcCtD
Paliperidone—Leukopenia—Ramipril—type 2 diabetes mellitus	4.26e-05	0.000281	CcSEcCtD
Paliperidone—Headache—Glyburide—type 2 diabetes mellitus	4.25e-05	0.000281	CcSEcCtD
Paliperidone—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.24e-05	0.00028	CcSEcCtD
Paliperidone—Hypotension—Losartan—type 2 diabetes mellitus	4.23e-05	0.000279	CcSEcCtD
Paliperidone—Palpitations—Ramipril—type 2 diabetes mellitus	4.21e-05	0.000278	CcSEcCtD
Paliperidone—Feeling abnormal—Metformin—type 2 diabetes mellitus	4.2e-05	0.000277	CcSEcCtD
Paliperidone—Decreased appetite—Irbesartan—type 2 diabetes mellitus	4.18e-05	0.000276	CcSEcCtD
Paliperidone—Loss of consciousness—Ramipril—type 2 diabetes mellitus	4.18e-05	0.000276	CcSEcCtD
Paliperidone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.17e-05	0.000275	CcSEcCtD
Paliperidone—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.17e-05	0.000275	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	4.16e-05	0.000274	CcSEcCtD
Paliperidone—Cough—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000274	CcSEcCtD
Paliperidone—Fatigue—Irbesartan—type 2 diabetes mellitus	4.15e-05	0.000274	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	4.13e-05	0.000272	CcSEcCtD
Paliperidone—Hypersensitivity—Valsartan—type 2 diabetes mellitus	4.13e-05	0.000272	CcSEcCtD
Paliperidone—Convulsion—Ramipril—type 2 diabetes mellitus	4.12e-05	0.000272	CcSEcCtD
Paliperidone—Pain—Irbesartan—type 2 diabetes mellitus	4.12e-05	0.000272	CcSEcCtD
Paliperidone—Constipation—Irbesartan—type 2 diabetes mellitus	4.12e-05	0.000272	CcSEcCtD
Paliperidone—Insomnia—Losartan—type 2 diabetes mellitus	4.1e-05	0.00027	CcSEcCtD
Paliperidone—Hypersensitivity—Orlistat—type 2 diabetes mellitus	4.08e-05	0.000269	CcSEcCtD
Paliperidone—Paraesthesia—Losartan—type 2 diabetes mellitus	4.07e-05	0.000268	CcSEcCtD
Paliperidone—Urticaria—Metformin—type 2 diabetes mellitus	4.05e-05	0.000267	CcSEcCtD
Paliperidone—Arthralgia—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000267	CcSEcCtD
Paliperidone—Myalgia—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000267	CcSEcCtD
Paliperidone—Chest pain—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000267	CcSEcCtD
Paliperidone—Dyspnoea—Losartan—type 2 diabetes mellitus	4.04e-05	0.000266	CcSEcCtD
Paliperidone—Anxiety—Ramipril—type 2 diabetes mellitus	4.04e-05	0.000266	CcSEcCtD
Paliperidone—Nausea—Glyburide—type 2 diabetes mellitus	4.03e-05	0.000266	CcSEcCtD
Paliperidone—Abdominal pain—Metformin—type 2 diabetes mellitus	4.03e-05	0.000266	CcSEcCtD
Paliperidone—Dizziness—Gliclazide—type 2 diabetes mellitus	4.03e-05	0.000266	CcSEcCtD
Paliperidone—Somnolence—Losartan—type 2 diabetes mellitus	4.03e-05	0.000266	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	4.02e-05	0.000266	CcSEcCtD
Paliperidone—Asthenia—Valsartan—type 2 diabetes mellitus	4.02e-05	0.000265	CcSEcCtD
Paliperidone—Discomfort—Ramipril—type 2 diabetes mellitus	4e-05	0.000264	CcSEcCtD
Paliperidone—Dyspepsia—Losartan—type 2 diabetes mellitus	3.99e-05	0.000263	CcSEcCtD
Paliperidone—Asthenia—Orlistat—type 2 diabetes mellitus	3.97e-05	0.000262	CcSEcCtD
Paliperidone—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.97e-05	0.000262	CcSEcCtD
Paliperidone—Pruritus—Valsartan—type 2 diabetes mellitus	3.96e-05	0.000261	CcSEcCtD
Paliperidone—Dry mouth—Ramipril—type 2 diabetes mellitus	3.96e-05	0.000261	CcSEcCtD
Paliperidone—Decreased appetite—Losartan—type 2 diabetes mellitus	3.94e-05	0.00026	CcSEcCtD
Paliperidone—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.00026	CcSEcCtD
Paliperidone—Confusional state—Ramipril—type 2 diabetes mellitus	3.92e-05	0.000258	CcSEcCtD
Paliperidone—Pruritus—Orlistat—type 2 diabetes mellitus	3.92e-05	0.000258	CcSEcCtD
Paliperidone—Fatigue—Losartan—type 2 diabetes mellitus	3.91e-05	0.000258	CcSEcCtD
Paliperidone—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3.88e-05	0.000256	CcSEcCtD
Paliperidone—Oedema—Ramipril—type 2 diabetes mellitus	3.88e-05	0.000256	CcSEcCtD
Paliperidone—Vomiting—Gliclazide—type 2 diabetes mellitus	3.88e-05	0.000256	CcSEcCtD
Paliperidone—Constipation—Losartan—type 2 diabetes mellitus	3.87e-05	0.000256	CcSEcCtD
Paliperidone—Pain—Losartan—type 2 diabetes mellitus	3.87e-05	0.000256	CcSEcCtD
Paliperidone—Rash—Gliclazide—type 2 diabetes mellitus	3.84e-05	0.000254	CcSEcCtD
Paliperidone—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.84e-05	0.000253	CcSEcCtD
Paliperidone—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.83e-05	0.000253	CcSEcCtD
Paliperidone—Urticaria—Irbesartan—type 2 diabetes mellitus	3.82e-05	0.000252	CcSEcCtD
Paliperidone—Shock—Ramipril—type 2 diabetes mellitus	3.82e-05	0.000252	CcSEcCtD
Paliperidone—Headache—Gliclazide—type 2 diabetes mellitus	3.82e-05	0.000252	CcSEcCtD
Paliperidone—Nervous system disorder—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000251	CcSEcCtD
Paliperidone—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.81e-05	0.000251	CcSEcCtD
Paliperidone—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.81e-05	0.000251	CcSEcCtD
Paliperidone—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.8e-05	0.000251	CcSEcCtD
Paliperidone—Tachycardia—Ramipril—type 2 diabetes mellitus	3.79e-05	0.00025	CcSEcCtD
Paliperidone—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.79e-05	0.00025	CcSEcCtD
Paliperidone—Skin disorder—Ramipril—type 2 diabetes mellitus	3.77e-05	0.000249	CcSEcCtD
Paliperidone—Feeling abnormal—Losartan—type 2 diabetes mellitus	3.73e-05	0.000246	CcSEcCtD
Paliperidone—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	3.7e-05	0.000244	CcSEcCtD
Paliperidone—Dizziness—Valsartan—type 2 diabetes mellitus	3.7e-05	0.000244	CcSEcCtD
Paliperidone—Anorexia—Ramipril—type 2 diabetes mellitus	3.7e-05	0.000244	CcSEcCtD
Paliperidone—Dizziness—Orlistat—type 2 diabetes mellitus	3.66e-05	0.000241	CcSEcCtD
Paliperidone—Asthenia—Metformin—type 2 diabetes mellitus	3.66e-05	0.000241	CcSEcCtD
Paliperidone—Hypotension—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000239	CcSEcCtD
Paliperidone—Nausea—Gliclazide—type 2 diabetes mellitus	3.62e-05	0.000239	CcSEcCtD
Paliperidone—Pruritus—Metformin—type 2 diabetes mellitus	3.61e-05	0.000238	CcSEcCtD
Paliperidone—Urticaria—Losartan—type 2 diabetes mellitus	3.6e-05	0.000237	CcSEcCtD
Paliperidone—Abdominal pain—Losartan—type 2 diabetes mellitus	3.58e-05	0.000236	CcSEcCtD
Paliperidone—Body temperature increased—Losartan—type 2 diabetes mellitus	3.58e-05	0.000236	CcSEcCtD
Paliperidone—Vomiting—Valsartan—type 2 diabetes mellitus	3.56e-05	0.000235	CcSEcCtD
Paliperidone—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	3.55e-05	0.000234	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000234	CcSEcCtD
Paliperidone—Rash—Valsartan—type 2 diabetes mellitus	3.53e-05	0.000233	CcSEcCtD
Paliperidone—Dermatitis—Valsartan—type 2 diabetes mellitus	3.53e-05	0.000233	CcSEcCtD
Paliperidone—Vomiting—Orlistat—type 2 diabetes mellitus	3.52e-05	0.000232	CcSEcCtD
Paliperidone—Insomnia—Ramipril—type 2 diabetes mellitus	3.51e-05	0.000232	CcSEcCtD
Paliperidone—Headache—Valsartan—type 2 diabetes mellitus	3.51e-05	0.000232	CcSEcCtD
Paliperidone—Diarrhoea—Metformin—type 2 diabetes mellitus	3.49e-05	0.00023	CcSEcCtD
Paliperidone—Rash—Orlistat—type 2 diabetes mellitus	3.49e-05	0.00023	CcSEcCtD
Paliperidone—Paraesthesia—Ramipril—type 2 diabetes mellitus	3.49e-05	0.00023	CcSEcCtD
Paliperidone—Dermatitis—Orlistat—type 2 diabetes mellitus	3.49e-05	0.00023	CcSEcCtD
Paliperidone—Headache—Orlistat—type 2 diabetes mellitus	3.47e-05	0.000229	CcSEcCtD
Paliperidone—Dyspnoea—Ramipril—type 2 diabetes mellitus	3.46e-05	0.000228	CcSEcCtD
Paliperidone—Asthenia—Irbesartan—type 2 diabetes mellitus	3.45e-05	0.000228	CcSEcCtD
Paliperidone—Somnolence—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000228	CcSEcCtD
Paliperidone—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000226	CcSEcCtD
Paliperidone—Pruritus—Irbesartan—type 2 diabetes mellitus	3.41e-05	0.000225	CcSEcCtD
Paliperidone—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.38e-05	0.000223	CcSEcCtD
Paliperidone—Dizziness—Metformin—type 2 diabetes mellitus	3.37e-05	0.000223	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.35e-05	0.000221	CcSEcCtD
Paliperidone—Fatigue—Ramipril—type 2 diabetes mellitus	3.35e-05	0.000221	CcSEcCtD
Paliperidone—Hypersensitivity—Losartan—type 2 diabetes mellitus	3.34e-05	0.00022	CcSEcCtD
Paliperidone—Nausea—Valsartan—type 2 diabetes mellitus	3.33e-05	0.00022	CcSEcCtD
Paliperidone—Constipation—Ramipril—type 2 diabetes mellitus	3.32e-05	0.000219	CcSEcCtD
Paliperidone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.29e-05	0.000217	CcSEcCtD
Paliperidone—Nausea—Orlistat—type 2 diabetes mellitus	3.29e-05	0.000217	CcSEcCtD
Paliperidone—Asthenia—Losartan—type 2 diabetes mellitus	3.25e-05	0.000214	CcSEcCtD
Paliperidone—Vomiting—Metformin—type 2 diabetes mellitus	3.24e-05	0.000214	CcSEcCtD
Paliperidone—Rash—Metformin—type 2 diabetes mellitus	3.22e-05	0.000212	CcSEcCtD
Paliperidone—Dermatitis—Metformin—type 2 diabetes mellitus	3.21e-05	0.000212	CcSEcCtD
Paliperidone—Pruritus—Losartan—type 2 diabetes mellitus	3.21e-05	0.000211	CcSEcCtD
Paliperidone—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000211	CcSEcCtD
Paliperidone—Headache—Metformin—type 2 diabetes mellitus	3.2e-05	0.000211	CcSEcCtD
Paliperidone—Dizziness—Irbesartan—type 2 diabetes mellitus	3.18e-05	0.00021	CcSEcCtD
Paliperidone—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.18e-05	0.00021	CcSEcCtD
Paliperidone—Diarrhoea—Losartan—type 2 diabetes mellitus	3.1e-05	0.000205	CcSEcCtD
Paliperidone—Urticaria—Ramipril—type 2 diabetes mellitus	3.09e-05	0.000204	CcSEcCtD
Paliperidone—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000203	CcSEcCtD
Paliperidone—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000203	CcSEcCtD
Paliperidone—Vomiting—Irbesartan—type 2 diabetes mellitus	3.06e-05	0.000202	CcSEcCtD
Paliperidone—Rash—Irbesartan—type 2 diabetes mellitus	3.04e-05	0.0002	CcSEcCtD
Paliperidone—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.03e-05	0.0002	CcSEcCtD
Paliperidone—Nausea—Metformin—type 2 diabetes mellitus	3.03e-05	0.0002	CcSEcCtD
Paliperidone—Headache—Irbesartan—type 2 diabetes mellitus	3.02e-05	0.000199	CcSEcCtD
Paliperidone—Dizziness—Losartan—type 2 diabetes mellitus	3e-05	0.000198	CcSEcCtD
Paliperidone—Vomiting—Losartan—type 2 diabetes mellitus	2.88e-05	0.00019	CcSEcCtD
Paliperidone—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.86e-05	0.000189	CcSEcCtD
Paliperidone—Nausea—Irbesartan—type 2 diabetes mellitus	2.86e-05	0.000189	CcSEcCtD
Paliperidone—Rash—Losartan—type 2 diabetes mellitus	2.86e-05	0.000188	CcSEcCtD
Paliperidone—Dermatitis—Losartan—type 2 diabetes mellitus	2.85e-05	0.000188	CcSEcCtD
Paliperidone—Headache—Losartan—type 2 diabetes mellitus	2.84e-05	0.000187	CcSEcCtD
Paliperidone—Asthenia—Ramipril—type 2 diabetes mellitus	2.79e-05	0.000184	CcSEcCtD
Paliperidone—Pruritus—Ramipril—type 2 diabetes mellitus	2.75e-05	0.000181	CcSEcCtD
Paliperidone—Nausea—Losartan—type 2 diabetes mellitus	2.69e-05	0.000178	CcSEcCtD
Paliperidone—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.66e-05	0.000175	CcSEcCtD
Paliperidone—Dizziness—Ramipril—type 2 diabetes mellitus	2.57e-05	0.000169	CcSEcCtD
Paliperidone—Vomiting—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000163	CcSEcCtD
Paliperidone—Rash—Ramipril—type 2 diabetes mellitus	2.45e-05	0.000162	CcSEcCtD
Paliperidone—Dermatitis—Ramipril—type 2 diabetes mellitus	2.45e-05	0.000161	CcSEcCtD
Paliperidone—Headache—Ramipril—type 2 diabetes mellitus	2.43e-05	0.000161	CcSEcCtD
Paliperidone—Nausea—Ramipril—type 2 diabetes mellitus	2.31e-05	0.000152	CcSEcCtD
Paliperidone—HRH1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.88e-06	2.2e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.88e-06	2.2e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.87e-06	2.2e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.87e-06	2.2e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.87e-06	2.19e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.87e-06	2.19e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.86e-06	2.18e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	1.86e-06	2.18e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	1.86e-06	2.18e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.85e-06	2.17e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.85e-06	2.17e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.85e-06	2.17e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	1.85e-06	2.17e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.85e-06	2.17e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.84e-06	2.16e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.84e-06	2.16e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.84e-06	2.16e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.84e-06	2.16e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.83e-06	2.15e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.83e-06	2.15e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.82e-06	2.14e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.82e-06	2.13e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.82e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.82e-06	2.13e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.81e-06	2.12e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.8e-06	2.11e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	1.8e-06	2.11e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.8e-06	2.11e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.79e-06	2.1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.79e-06	2.1e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.78e-06	2.09e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	1.78e-06	2.09e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.77e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.77e-06	2.08e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.76e-06	2.07e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.76e-06	2.07e-05	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.75e-06	2.06e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.75e-06	2.06e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.75e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.74e-06	2.04e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.74e-06	2.04e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.73e-06	2.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.73e-06	2.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.73e-06	2.04e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.73e-06	2.03e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.72e-06	2.02e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.71e-06	2.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.71e-06	2.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.71e-06	2.01e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.71e-06	2e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.71e-06	2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.7e-06	2e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.7e-06	2e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.7e-06	2e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.7e-06	2e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.7e-06	2e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.7e-06	2e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.7e-06	1.99e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.7e-06	1.99e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.69e-06	1.99e-05	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.69e-06	1.99e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.69e-06	1.98e-05	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.68e-06	1.98e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.68e-06	1.97e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.68e-06	1.97e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.68e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.67e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.67e-06	1.97e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.67e-06	1.96e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.67e-06	1.96e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.67e-06	1.96e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.67e-06	1.96e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.66e-06	1.95e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.65e-06	1.94e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.65e-06	1.94e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.65e-06	1.93e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.64e-06	1.93e-05	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.64e-06	1.92e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.63e-06	1.92e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.63e-06	1.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.63e-06	1.91e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.62e-06	1.91e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.62e-06	1.9e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.62e-06	1.9e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.61e-06	1.9e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.61e-06	1.89e-05	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.61e-06	1.89e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.61e-06	1.89e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.6e-06	1.88e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.6e-06	1.88e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.6e-06	1.88e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.6e-06	1.87e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.6e-06	1.87e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.59e-06	1.87e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.59e-06	1.86e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.58e-06	1.86e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.58e-06	1.85e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.57e-06	1.85e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.57e-06	1.84e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.56e-06	1.83e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.56e-06	1.83e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.55e-06	1.82e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.55e-06	1.82e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.54e-06	1.8e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.53e-06	1.8e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.53e-06	1.8e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.52e-06	1.78e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.52e-06	1.78e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.51e-06	1.78e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.51e-06	1.77e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.5e-06	1.76e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.49e-06	1.75e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.49e-06	1.75e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.49e-06	1.75e-05	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.49e-06	1.74e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.47e-06	1.73e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.47e-06	1.73e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.47e-06	1.72e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.46e-06	1.72e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.46e-06	1.72e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.46e-06	1.72e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.46e-06	1.72e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.46e-06	1.72e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.46e-06	1.71e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.45e-06	1.71e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.45e-06	1.7e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.44e-06	1.7e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.44e-06	1.69e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.44e-06	1.69e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.43e-06	1.68e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.42e-06	1.67e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.42e-06	1.67e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.42e-06	1.66e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.41e-06	1.66e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.41e-06	1.65e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.41e-06	1.65e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.39e-06	1.63e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.39e-06	1.63e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.38e-06	1.62e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.38e-06	1.62e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.38e-06	1.62e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.38e-06	1.62e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.38e-06	1.62e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.38e-06	1.62e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.37e-06	1.61e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.37e-06	1.6e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.36e-06	1.6e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.35e-06	1.59e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.35e-06	1.59e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.35e-06	1.59e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.35e-06	1.59e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.35e-06	1.58e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.34e-06	1.57e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.33e-06	1.56e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.33e-06	1.56e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.33e-06	1.56e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.33e-06	1.56e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.32e-06	1.56e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	1.32e-06	1.55e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.32e-06	1.55e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.32e-06	1.55e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.31e-06	1.54e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.31e-06	1.53e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.3e-06	1.53e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.3e-06	1.53e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.29e-06	1.52e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.28e-06	1.51e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.28e-06	1.51e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.28e-06	1.5e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.27e-06	1.5e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	1.27e-06	1.49e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.26e-06	1.48e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.26e-06	1.48e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.26e-06	1.48e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.26e-06	1.48e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.26e-06	1.48e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.25e-06	1.47e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.25e-06	1.46e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.24e-06	1.46e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.24e-06	1.45e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.24e-06	1.45e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.23e-06	1.45e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.23e-06	1.45e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.23e-06	1.44e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.23e-06	1.44e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.23e-06	1.44e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	1.43e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.22e-06	1.43e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.21e-06	1.42e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.21e-06	1.42e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.21e-06	1.42e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.2e-06	1.41e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.2e-06	1.4e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.19e-06	1.4e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.18e-06	1.39e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.17e-06	1.38e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.15e-06	1.35e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.15e-06	1.35e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.14e-06	1.34e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.13e-06	1.33e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.13e-06	1.33e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.13e-06	1.32e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.13e-06	1.32e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.12e-06	1.32e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.12e-06	1.31e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.11e-06	1.31e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.11e-06	1.3e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.11e-06	1.3e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.1e-06	1.3e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.1e-06	1.3e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.08e-06	1.27e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.08e-06	1.26e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.06e-06	1.24e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.06e-06	1.24e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.06e-06	1.24e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	1.05e-06	1.23e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.04e-06	1.23e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.04e-06	1.22e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.03e-06	1.21e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.02e-06	1.2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.01e-06	1.18e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	9.84e-07	1.16e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	9.79e-07	1.15e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	9.52e-07	1.12e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.4e-07	1.1e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.37e-07	1.1e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	9.19e-07	1.08e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.08e-07	1.07e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.03e-07	1.06e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	9.02e-07	1.06e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.78e-07	1.03e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.64e-07	1.02e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	8.64e-07	1.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	8.53e-07	1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	8.5e-07	9.98e-06	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.48e-07	9.96e-06	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	8.32e-07	9.77e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	8.27e-07	9.71e-06	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.97e-07	9.36e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	7.91e-07	9.29e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	7.91e-07	9.29e-06	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.84e-07	9.21e-06	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.82e-07	9.19e-06	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	7.82e-07	9.18e-06	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.73e-07	9.08e-06	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.68e-07	9.02e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	7.23e-07	8.49e-06	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.13e-07	8.38e-06	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	5.56e-07	6.53e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	3.63e-07	4.27e-06	CbGpPWpGaD
